Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

File(s)

1-s2.0-S0140673615610741-main.pdf (638.57 KB)

Published version

Show more

Author(s)

Dowsett, M

Forbes, JF

Bradley, R

Ingle, J

Aihara, T

more

Type

Journal Article

Date Issued

2015-07-24

Date Acceptance

2015-07-24

Citation

LANCEt, 2015, 386 (10001), pp.1341-1352

URI

http://hdl.handle.net/10044/1/32438

DOI

https://www.dx.doi.org/10.1016/S0140-6736(15)61074-1

ISSN

0140-6736

Publisher

Elsevier

Start Page

1341

End Page

1352

Journal / Book Title

LANCEt

Volume

386

Issue

10001

Copyright Statement

© Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 2015. Open Access article distributed under the terms of CC BY.

License URL

http://creativecommons.org/licenses/by/4.0/

Subjects

Science & Technology

Life Sciences & Biomedicine

Medicine, General & Internal

General & Internal Medicine

ADJUVANT ENDOCRINE THERAPY

BONE-MINERAL DENSITY

PHASE-III TRIAL

POSTMENOPAUSAL WOMEN

CONTINUED TAMOXIFEN

AUSTRIAN BREAST

BIG 1-98

ANASTROZOLE

EXEMESTANE

LETROZOLE

Antineoplastic Agents, Hormonal

Aromatase Inhibitors

Breast Neoplasms

Drug Administration Schedule

Female

Humans

Randomized Controlled Trials as Topic

Tamoxifen

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

11 Medical And Health Sciences

Publication Status

Published